{"id":"W4388277800","doi":"10.1016/j.oraloncology.2023.106587","title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence","year":2023,"lang":"en","type":"article","venue":"Oral Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Astellas Pharma; National Institute for Health and Care Research; Genentech; Coherus Biosciences; Novartis Pharma; Rakuten Medical; Seagen; Incyte; Eisai; National Comprehensive Cancer Network; Sanofi; Exelixis; Medpace; Yuhan; Gilead Sciences; Amgen; Pfizer; Les Laboratories Pierre Fabre; PharmaMar; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Cetuximab; Docetaxel; Oncology; Internal medicine; Head and neck squamous-cell carcinoma; Subgroup analysis; Hazard ratio; Head and neck cancer; Chemotherapy; Radiation therapy; Cancer; Immunotherapy; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004851315,0.001071284,0.003175065,0.0006352914,0.0002446938,0.0008919362,0.0009099919,0.00123415,0.00246851],"category_scores_gemma":[0.003829075,0.0005096685,0.009575448,0.0006168539,0.0003671525,0.0005702673,0.0005145219,0.001292965,0.0003172087],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009844783,"about_ca_system_score_gemma":0.0008624446,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001386692,"about_ca_topic_score_gemma":0.003935766,"domain_scores_codex":[0.9977323,0.00122684,0.0003033915,0.0003205648,0.0001782073,0.0002387223],"domain_scores_gemma":[0.9982547,0.0008147073,0.0004399119,0.0002466137,0.00006722442,0.0001768228],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8858839,0.001051042,0.02811662,0.001721055,0.05093433,0.0002189795,0.0001197265,0.002025024,0.003788411,0.0001199741,0.001224396,0.02479658],"study_design_scores_gemma":[0.4558153,0.1903785,0.1751869,0.0006271372,0.1545707,0.001056882,0.0004437977,0.008985412,0.006029047,0.001836841,0.004865806,0.0002037528],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9878945,0.008993945,0.0004373918,0.0001966342,0.0001608608,0.0005132433,0.001005351,0.00002923704,0.0007689012],"genre_scores_gemma":[0.9965985,0.001185046,0.0002795973,0.0002228659,0.0001167036,0.0003715968,0.0006617585,0.000009225482,0.000554676],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004851315,"threshold_uncertainty_score":0.02565652,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07502603304476131,"score_gpt":0.3833777990868101,"score_spread":0.3083517660420488,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}